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AbstrACt
Introduction Despite the high number of frozen embryo 
transfer (FET) cycles being conducted (190 000 cycles/
year) in Europe, the timing of blastocyst transfer and the 
use of luteal phase progesterone support in modified 
natural cycle FET (mNC- FET) in assisted reproductive 
technologies are controversial. In mNC- FET, the timing of 
blastocyst warming and transfer is determined according 
to the time of implantation in a natural cycle, aiming to 
reach blastocyst endometrial synchronicity. However, 
the optimal day of blastocyst transfer following ovulation 
trigger is not determined. In addition, the value of luteal 
phase support to maintain the endometrium remains 
uncertain. Thus, there is a need to identify the optimal 
timing of blastocyst warming and transfer and the effect 
of luteal phase support in a randomised controlled trial 
design. The aim of this randomised controlled trial is to 
investigate if progesterone supplementation from the early 
luteal phase until gestational age 8 weeks is superior to no 
progesterone supplementation and to assess if blastocyst 
warming and transfer 6 days after ovulation trigger is 
superior to 7 days after ovulation trigger in mNC- FET with 
live birth rates as the primary outcome.
Methods and analysis Multicentre, randomised, 
controlled, single- blinded trial including 604 normo- 
ovulatory women aged 18–41 years undergoing mNC- FET 
with a high- quality blastocyst originating from their first to 
third in vitro fertilisation/intracytoplasmic sperm injection 
cycle. Participants are randomised (1:1:1:1) to either luteal 
phase progesterone or no luteal phase progesterone and to 
blastocyst warming and transfer on day 6 or 7 after human 
chorionic gonadotropin trigger. Only single blastocyst 
transfers will be performed.
Ethics and dissemination The study is approved by 
the Danish Committee on Health Research Ethics (H-
18025839), the Danish Medicines Agency (2018061319) 
and the Danish Data Protection Agency (VD-2018-381). 
The results of the study will be publicly disseminated.
trial registration number The study is registered in 
EudraCT (2018-002207-34) and on  ClinicalTrials. gov 
(NCT03795220); Pre- results.
IntroduCtIon
The use of assisted reproductive technology 
(ART) is increasing and over 5% of the birth 
cohort in Denmark,1 and in several other 
European countries,2 is conceived by ART. 
In recent years, the use of frozen- thawed 
embryo transfer (FET) has become more 
frequent, exceeding the number of fresh 
strengths and limitations of the study
 ► The study will be conducted as a randomised con-
trolled trial concerning both the use of luteal phase 
progesterone supplementation and timing of blasto-
cyst transfer in modified natural cycle frozen embryo 
transfer (mNC- FET), providing important information 
on how to optimise mNC- FET.
 ► The secondary outcomes of this study will offer 
insight into the endocrine profile of a cycle with or 
without conception as well as gynaecological, ob-
stetrical and neonatal outcomes for women using or 
not using luteal phase progesterone supplementa-
tion in mNC- FET.
 ► The broad inclusion criteria ensure generalisabil-
ity and a high degree of applicability of the study 
results.
 ► Optimising mNC- FET may lead to higher live birth 
rates, shorter time from start of treatment to preg-
nancy and a reduction in expenses following FET.
 ► The study is powered to detect a 10% difference in 
live birth rates; thus, smaller but clinically relevant 
differences may be overlooked.
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in vitro fertilisation (IVF) cycles (190 000 FET cycles vs 
146 000 fresh IVF cycles/year in Europe).2 In parallel, 
the pregnancy rates after FET have increased and may 
pass those reached with fresh embryo transfer.3–6 FET 
has several advantages. With the possibility to freeze all 
surplus embryos, the need for frequent oocyte retrievals 
in case of an unsuccessful fresh cycle is reduced. Without 
the need to stimulate follicle development, the risk of 
developing ovarian hyperstimulation syndrome, one 
of the most severe side effects of ART, is eliminated. 
Furthermore, with FET, single blastocyst transfer can be 
used without compromising cumulative live birth results, 
which is a major advantage as singleton pregnancies carry 
less obstetric and perinatal risks than twin pregnancies.7 
Lastly, singletons conceived after FET have a lower risk 
of preterm birth, low birth weight and being small for 
gestational age. However, they do have a higher risk of 
being large for gestational age compared with singletons 
conceived after fresh embryo transfer.8–10 Hypertensive 
disorders during pregnancy are also reported to be more 
prevalent after FET versus fresh embryo transfers.8 10 11
In women with regular menstrual cycles, FET can be 
planned in true natural cycles (tNC- FET) with timing 
based on monitoring of the naturally occurring luteinising 
hormone (LH) peak or in human chorionic gonadotropin 
(hCG)–triggered modified natural cycles (mNC- FET). In a 
natural cycle, the ascending leg of the LH peak starts when 
the dominant follicle reaches 17 to 18 mm.12–14 However, in 
some women, the LH peak is not present until the follicle is 
22–23 mm and in others it may be present with a follicle size 
smaller than 17 mm. Hence, it may be hypothesised that in 
some patients, an apparent follicle of 17 mm is not a fully 
mature or healthy follicle and may thus secrete subnormal 
levels of progesterone and oestradiol from the corpus 
luteum after hCG triggering. In others, an early endoge-
nous LH peak could cause a premature luteinisation of the 
endometrium and thereby asynchrony between the endo-
metrium and the transferred blastocyst. Moreover, it has 
been suggested that the hCG trigger used in a modified 
natural cycle may affect reproductive outcomes by a nega-
tive feedback mechanism that inhibits endogenous GnRH 
secretion resulting in subnormal LH secretion causing a 
luteal phase insufficiency.15 16
To solve the potential lack of endogenous LH or a subop-
timal corpus luteum, many fertility clinics use luteal phase 
progesterone support to improve implantation rates in FET. 
Even so, in mNC- FET there is currently no consensus on the 
effect of luteal phase progesterone supplementation.17–19 
In tNC- FET, a randomised controlled trial (RCT) including 
435 patients and a retrospective study with 1972 patients 
reported higher live birth rates, when vaginal progesterone 
was added from the day of high- grade blastocyst or day 2 
embryo transfers, respectively.20 21 In mNC- FET, two retro-
spective studies of 131 and 228 patients reported a higher 
clinical pregnancy rate and a higher live birth rate when 
vaginal progesterone was administered.22 23 Another retro-
spective study found similar ongoing pregnancy rates in 452 
women with or without the use of vaginal progesterone.24 
Finally, a smaller RCT with 102 patients showed no supe-
riority of intramuscular progesterone versus no treatment 
in terms of clinical pregnancy rates.25 However, there was a 
trend towards a higher clinical pregnancy rate with proges-
terone supplementation in the latter study. These contra-
dictory and sparse data on the use of luteal phase support 
in mNC- FET emphasise the importance of a sufficiently 
powered RCT to assess the efficacy of progesterone in 
mNC- FET.
To achieve a successful implantation, synchronicity of 
blastocyst developmental stage and the endometrium is 
important. The timing of blastocyst warming and transfer 
in a FET cycle is based on the timing in a natural cycle, 
with warming and transfer of a day 5 blastocyst 5 days after 
suspected ovulation. Even so, the optimal day of transfer in 
mNC- FET has been debated. In the substituted FET cycle, 
only a few RCTs have tested the optimal day of embryo 
transfer26 27; however, no RCTs have been conducted 
within tNC- FET or mNC- FET. A recent review based on 
retrospective studies suggests both warming and transfer 
of blastocysts on hCG trigger +7 days in mNC- FET,28 while 
the standard in Danish fertility clinics is either blastocyst 
warming and transfer on hCG trigger +6 or +7 days. To 
explore FET timing in the modified natural cycle, this 
RCT will assess if warming and transfer 6 days after hCG is 
superior to warming and transfer 7 days after hCG trigger 
in terms of live birth rates per transfer.
objECtIvEs
Primary objective
The primary objectives of the study are to investigate if 
luteal phase progesterone support in mNC- FET is supe-
rior to no luteal phase support, and if blastocyst warm-
ing+transfer 6 days after hCG trigger is superior to 
warming+transfer 7 days after hCG trigger, in terms of live 
birth rates per transfer.
secondary objectives
1. To investigate endocrine profiles in blood samples of 
women undergoing mNC- FET with or without luteal 
phase progesterone support.
2. To compare treatment outcomes including biochemi-
cal and clinical pregnancy rates, miscarriage rates and 
obstetric complications.
3. To compare neonatal outcomes (birth weight and 
length, gestational age, malformations and admission 
to neonatal intensive care unit).
4. To compare self- reported welfare and health of women 
receiving and not receiving luteal phase progesterone 
support.
MEthods And AnAlysIs
study design
The study is designed as a multicentre, randomised, 
controlled, single- blinded trial with participation of seven 
public fertility clinics in Denmark. All seven clinics are 
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Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age 18–41
Regular menstrual cycle 
(23–35 days)
Undergoing FET
Vitrified blastocyst from 1st 
to 3rd IVF/ICSI cycle in a 
public hospital
Blastocyst Gardner score 
3–6 A/B
Uterine malformations
Submucosal uterine myomas
Uterine polyps
Allergy to study medication
Contraindication to study 
medication
HIV and hepatitis B/C
Testicular sperm aspiration
Preimplantation genetic testing
Known indication for luteal 
phase progesterone support
FET, frozen embryo transfer; HIV, Human immunodeficiency virus; 
ICSI, intracytoplasmic sperm injection; IVF, in vitro fertilisation.
part of a University Hospital setting and all hospitals 
perform standardised treatments according to the public 
healthcare system in Denmark. Patient enrolment began 
in January 2019 and continues until January 2021. For 
a list of the participating hospitals, contact  marte. saup-
stad@ regionh. dk.
The SPIRIT guidelines were used in development of 
this protocol.29
Patient and public involvement
Development of this research protocol was done without 
patient involvement; however, experiences of the first 
patients included in the study encouraged us to include 
an assessment of self- reported welfare and health. The 
final study results will be disseminated to participants on 
request.
study population/participants and recruitment
The study population will consist of 604 women under-
going mNC- FET after IVF or intracytoplasmic sperm 
injection (ICSI) treatment at one of the seven partici-
pating clinics. It is clinical routine that patients scheduled 
for FET call the fertility clinic on the first day of their 
menstrual bleeding. Subsequently, a study nurse or a 
non- treating doctor will identify and contact the patients 
who fulfil the inclusion and exclusion criteria to invite 
them to participate in the study. If the patient consents, 
a mail will be sent containing patient information about 
the study, and an appointment with a study nurse or a 
doctor will be set up at cycle days (CD) 2–5. During the 
first appointment (CD 2–5), the patient will be informed 
about the study and have the opportunity to ask ques-
tions. If she wishes to participate, informed consent forms 
will be filled out (online supplementary files 1–3). Final 
screening, including blood samples and an ultrasound 
examination of the uterus and ovaries, is done during the 
first consultation, confirming that all inclusion criteria 
are met.
To further explore how the endocrine profile and metab-
olism is affected during fertility treatment, a subgroup of 
40 patients receiving and 40 patients not receiving vaginal 
progesterone will have additional blood samples taken 
twice preovulatory and at four to five timepoints during 
the luteal phase, to detect endocrine profiles that may or 
may not be compatible with conception. Study subjects 
for the substudy analyses will be included consecutively at 
only two clinics—Rigshospitalet, Copenhagen University 
Hospital and Horsens Regional Hospital—until the goal 
of 40 patients in each of the two study groups is met.
Eligibility criteria
To participate in the study, women will have to meet the 
following inclusion criteria: age 18–41; regular menstrual 
cycle (23–35 days); undergoing frozen- thawed blastocyst 
transfer; vitrified blastocyst derived from first to third 
IVF/ICSI cycle with Gardner score 3–6 and inner cell mass 
and trophectoderm quality A and B30 (table 1). Exclusion 
criteria are uterine malformations, submucosal uterine 
myomas, uterine polyps, HIV, hepatitis B/C, testicular 
sperm aspiration, preimplantation genetic testing, known 
indication for luteal phase progesterone support, allergy 
to the study medication and contraindications to the 
study medication (table 1).
Further, for patients participating in the substudy, treat-
ment for thyroid disorders is an exclusion criterium.
A patient can withdraw from the study at any time. The 
patient participation in the study can also be interrupted 
by the non- treating or treating doctors, if one of the 
following criteria is present:
 ► The patient’s general condition contraindicates 
participation in the study.
 ► Protocol violation which the investigator considers 
having influence on the study outcome.
treatment and interventions
On cycle day 10–12, the patient undergoes transvaginal 
ultrasound to measure the dominant follicle and the 
endometrium. When the dominant follicle measures 
≥17 mm, randomisation is performed and the ovulation 
trigger (6500 IU hCG s.c.) is administered at 22:00 the 
same day. If the dominant follicle does not meet the 
size criteria on cycle days 10–12, subsequent scans are 
planned, following the patient until the dominant follicle 
meets the size criterium. Randomisation is carried out by 
a study nurse or a non- treating doctor using a randomis-
ation programme. Patients are randomised 1:1:1:1 to one 
of the four groups:
A. Luteal phase progesterone and warming+transfer 6 
days after hCG trigger.
B. Luteal phase progesterone and warming+transfer 7 
days after hCG trigger.
C. No luteal phase support and warming+transfer 6 days 
after hCG trigger.
D. No luteal phase support and warming+transfer 7 days 
after hCG trigger.
The patients randomised to luteal phase progesterone 
supplementation will receive the study medication and an 
instruction in administration of 100 mg vaginal proges-
terone (Lutinus; Ferring Pharmaceuticals) three times 
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Table 2 Overview of blood samples
Baseline (CD 2–5) AMH
Oestradiol
FSH
LH
Progesterone
ALAT
ASAT
TSH
Free T4
TPO antibodies
TG antibodies
Day of hCG trigger Oestradiol
FSH
LH
OH- Progesterone
Progesterone
TSH
Free T4
Day of ovulation
(hCG trigger+2 days)
Oestradiol
Progesterone
β-hCG
  
Day of blastocyst 
transfer (hCG 
trigger+6/7 days)
Oestradiol
FSH
LH
OH- Progesterone
Progesterone
β-hCG
TSH
Free T4
Mid- luteal phase (hCG 
trigger+11 days)
Oestradiol
FSH
LH
OH- Progesterone
Progesterone
β-hCG
TSH
Free T4
hCG trigger+14 days   Oestradiol
FSH
LH
OH- Progesterone
Progesterone
β-hCG
TSH
Free T4
Pregnancy test (hCG 
trigger+16 days)
β-hCG Oestradiol
FSH
LH
OH- Progesterone
Progesterone
TSH
Free T4
Day hCG trigger+19 
days*
  Oestradiol
FSH
LH
OH- Progesterone
Progesterone
β-hCG
TSH
Free T4
*Only if pregnancy test at trigger+16 days is positive.
ALAT, Alanine aminotransferase; AMH, Anti- Müllerian hormone; 
ASAT, Aspartate aminotransferase; Free T4, Free thyroxine; 
FSH, Follicle stimulating hormone; β-hCG, β-human chorionic 
gonadotropin; LH, Luteinizing hormone; TG antibodies, 
Thyroglobulin antibodies; TPO antibodies, Thyroid peroxidase 
antibodies; TSH, Thyroid- stimulating hormone.
daily starting the morning of day 4 after hCG trigger. 
Complete medicine accounts will be kept by the study 
nurses at each of the trial sites. All medication handed 
out to the patients will be recorded, and patients are 
instructed to inform the study personnel about deviations 
in medicine administration. Concomitant use of prescrip-
tion medication will be recorded in the study database, 
and study participants are excluded if they use medica-
tion that influences the enzyme CYP34.
On day 6 or 7 after the hCG trigger, the blastocyst with 
the highest implantation potential based on morpholog-
ical criteria is transferred by a treating doctor.
Patients randomised to vaginal progesterone will 
continue administration of the study medication until 
hCG trigger+16 days where a pregnancy test will be made. 
If the test is positive, patients randomised to progesterone 
support will continue using vaginal progesterone for 
another 30 days. If the test is negative, all medication will 
be discontinued.
randomisation
The randomisation program (dOxos CDS AB) uses a 
minimisation algorithm balancing the following vari-
ables: study ID (including information about trial site), 
age, number of previous oocyte retrievals, number of 
previous FETs and blastocyst Gardner score of the vitrified 
blastocyst with the highest implantation potential. The 
treatment arm that provides the optimal balance between 
the groups, minimising the difference of the means, is 
selected with high probability. The program also ensures 
an equal distribution of subjects in each treatment group 
in the study and at each trial site.
blinding procedure
The study is a single- blinded study; therefore, the study 
medication will be blinded for the treating doctors, but 
not for the patients, the non- treating doctors or the 
study nurses. The participants will not take progesterone 
the morning of the blastocyst transfer, but immediately 
after, to keep the treating doctors blinded. Patients will 
be instructed in not disclosing their study group to the 
treating doctors.
data collection
Treatment- related data are collected at the following time 
points: (1) baseline (CD 2–5), (2) day of hCG trigger, (2a) 
day of ovulation (hCG tigger+2 days), (3) day of blastocyst 
transfer (hCG trigger+6/7 days), (4) mid- luteal phase 
(hCG trigger+11 days) and at (5) hCG trigger+16 days. 
In case of a pregnancy, outcome data will be collected 
from the early pregnancy scan and from the patient’s 
and patient’s child’s medical records up to 1 year after 
delivery.
sample collection
Blood samples will be collected at timepoints 1 to 5 
during the treatment period. Patients participating in 
the substudy will have additional samples taken at all 
timepoints including samples taken at hCG trigger+14 
days and hCG trigger+19 days, depicted in table 2. Only 
patients recruited at Rigshospitalet will have samples 
taken at the day of ovulation (hCG trigger+2 days).
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research biobank and biobank for prospective research 
projects
An extra blood sample of 8–14 mL (whole blood, serum 
and plasma) will be taken at every sampling point, except 
timepoint 2a, and stored in a freezer. The samples will 
be stored for prospective analyses of new hormones or 
endocrine biomarkers related to reproductive medicine 
in this or future research projects approved by the Danish 
Committee on Health Research Ethics. When patient 
inclusion is completed, all biobank samples will be trans-
ported to Rigshospitalet.
If samples are not used, they will be destroyed according 
to the rules of destruction of biological material after end 
of the study or no later than 5 years after inclusion of the 
last patient. No biological material will be transferred for 
analyses outside Denmark.
Patients will sign a separate informed consent form for 
storage of samples in a biobank for future research proj-
ects (online supplementary file 3).
transvaginal ultrasound scans
During screening and until the patient meets the crite-
rium for the hCG trigger, transvaginal ultrasound scans 
will be performed according to the clinical routine in 
FET cycles. At baseline, an ultrasound examination will 
estimate the endometrial thickness, the size of the ovaries 
and the number of antral follicles. On the day of the hCG 
trigger, endometrial thickness, morphology, echogenicity 
as well as the presence of one or more follicles ≥17 mm will 
be recorded. If in doubt whether a preovulatory follicle is 
present, endometrial thickness and morphology in addi-
tion to serum progesterone level will be considered. If the 
patient conceives, an early transvaginal pregnancy scan 
will be made at gestational age 7–8 weeks for estimation 
of crown–rump length and viability.
Questionnaires
Having patient well- being as a focus point, the partici-
pating women will be asked to fill out questionnaires at 
timepoints 1 and 4. The questionnaires consist of stan-
dardised and validated questions targeted to explore 
self- assessed health, welfare and the emotional aspects of 
going through fertility treatment in addition to registra-
tion of possible study medication side effects.
data management
Data are transferred to an online eCRF; REDCap. The 
REDCap database has a complete audit trail and is based 
on anonymous subject ID numbers used in the trial. For 
numerical values (eg, blood sample values), data ranges 
are programmed to avoid gross typing errors. Data are 
backed up daily and stored on a server located in a locked 
facility in Denmark. Data registered in the trial will be 
monitored by the Danish Good Clinical Practice Unit.
Only research personnel at Copenhagen University 
Hospital, Rigshospitalet will have access to the final 
dataset. Ownership of data is determined by co- operation 
agreements as well as data processing agreements between 
Copenhagen University Hospital, Rigshospitalet (Capital 
Region of Denmark) and the participating hospitals.
data sharing plan
On request, the study protocol and deidentified indi-
vidual study data collected during the trial, including 
stored biobank samples, can be shared with research 
groups with relevant aims and a methodologically sound 
proposal. Approvals by necessary ethics committees and 
the Danish Data Protection Agency will be needed before 
sharing of data. All costs for data sharing will be covered 
by the party requesting the data. Data cannot be shared 
with groups working on research projects with the same 
aims, secondary aims or purposes. Further, no data can 
be shared until 3 months after publication of first papers 
on the primary and secondary outcomes in this study. 
Biobank samples cannot be shared with research groups 
outside Denmark. Proposals of data sharing should be 
directed to  anja. bisgaard. pinborg@ regionh. dk. To gain 
access, the requesting party will need to sign a data 
sharing agreement.
statistics
Outcome measurements
The primary endpoint is live birth rate per transfer, 
comparing the luteal phase progesterone groups with 
the no luteal phase progesterone groups and the warm-
ing+transfer day 6 groups with the warming+transfer day 
7 groups. Additional endpoints include assessment of 
other relevant aspects of mNC- FET including chem-
ical and clinical pregnancy rates, miscarriage rates, and 
obstetric and neonatal outcomes in the study groups. 
Furthermore, endocrine blood samples will be collected 
in all study groups to determine if an endocrine profile 
compatible and not compatible with conception can 
be identified. Lastly, self- reported welfare and health of 
patients receiving and not receiving vaginal luteal phase 
support will be compared.
Sample size calculation
The study is designed as a superiority study that allows 
detection of an effect size of 10% increase in live birth 
rates per transfer in
Comparison I: Vaginal progesterone (group A+B) 
versus no vaginal progesterone (groups C+D), and
Comparison II: Blastocyst warming+transfer day 6 
after hCG trigger (group A+C) versus blastocyst warm-
ing+transfer day 7 after hCG trigger (group B+D).
Power calculations were performed with SAS Enterprise 
Guide V.7.1. For a one- sided χ2 test comparing groups 
A+B with group C+D, we found that a total of 604 patients 
would be needed to detect an increase in live birth rate 
from 21% in group C+D to 31% in group A+B with 80% 
power and similarly when comparing group A+C with 
group B+D. The significance level for the power calcu-
lation was set to 2.5% to limit the overall risk of a false- 
positive result when testing the two co- primary hypotheses 
to 5% (Bonferroni adjustment). Due to the balanced 
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study design, mutual adjustment between the two treat-
ments was not considered in the power calculation.
Statistical analyses
For comparisons between the study groups, Student’s 
t- test for continuous variables and Kruskal- Wallis test, in 
case of non- parametric data, will be used. For compari-
sons of proportions, we will use χ2 tests. For the adjusted 
analyses, we will use multiple linear and logistic regres-
sion analyses for continuous endpoints and proportions, 
respectively. A significance level of less than 0.05 will be 
considered as statistically significant.
EthICs And dIssEMInAtIon
The safety of participants in all study groups is high. All 
medication used in the study is part of standard ART 
care. To ensure patient well- being, the investigators will 
monitor and evaluate potential side effects of the study 
medication at every clinical visit until end of progesterone 
treatment. As late side effects are unlikely with proges-
terone, there will be no further follow- up.
As the medication is well known, serious adverse reac-
tions (SARs) or suspected unexpected serious adverse 
reactions (SUSARs) are not expected. However, should 
a study participant experience a SAR or a SUSAR, the 
investigator will stop the treatment for that specific study 
participant immediately and report to the sponsor within 
24 hours. The participant will be withdrawn from the 
study.
No financial incentives exist for participation in the 
study, as the first three ART treatments with following 
FETs are covered by the public healthcare system in 
Denmark. The labelled study medication will be provided 
to the participants at each of the trial sites for free.
Positive, negative and inconclusive results will be 
published in international scientific journals and online 
( www. ClinicalTrials. gov). The results of the study will be 
presented at national as well as international scientific 
congresses and published in high- impact international 
scientific journals in reproductive medicine such as 
Human Reproduction or Fertility and Sterility. Further 
results of public interest will be reported in the public 
press.
dIsCussIon
The increasing use of FET and the lack of consensus 
regarding use of progesterone supplementation and 
timing of blastocyst warming and transfer in mNC- FET 
emphasise the need for additional studies. A major chal-
lenge comparing the existing studies on mNC- FET is 
the many different protocols, methods and traditions. 
Among the retrospective studies on luteal phase support 
in mNC- FET, one study used freezing of two pronuclear 
stage embryos,22 another used embryos cryopreserved 
on culture day 324 and a third study used data from both 
embryo and blastocyst transfers,23 while the only RCT 
available used cleavage stage embryos.25 In the same 
studies, administration of progesterone was started at 
different time points after hCG trigger and administered 
both as vaginal suppositories and as intramuscular injec-
tions. Moreover, some of the existing studies are based 
on multiple embryo transfers, while today’s clinical prac-
tice in Scandinavia is transfer of a single vitrified/warmed 
blastocyst.
Regarding the sample size calculation, it has been 
discussed whether the two interventions can be consid-
ered as being independent. As for luteal phase support, 
it may have a greater effect in patients with an undiscov-
ered corpus luteum insufficiency; however, as a corpus 
luteum insufficiency would affect the entire luteal phase, 
the outcome is expected to be independent of the day 
of the blastocyst transfer. Further, regarding the timing 
of blastocyst transfer, a surge in LH prior to hCG trigger 
(dominant follicle ≥17 mm) carries the risk of prema-
ture progesterone synthesis and blastocyst–endometrium 
asynchrony. However, a premature luteinisation of the 
endometrium would be independent of introduction of 
luteal phase support or no luteal phase support at hCG 
trigger+4 days.
The strengths of this study are the multicentre, 
randomised, controlled, single- blinded trial design, high 
generalisability of the study results and publication of the 
study protocol for increased transparency in research. 
To further improve the study method, a double- blinded 
design would have been optimal. However, as no placebo 
drug was available, it was decided to keep the treating 
doctors blinded to reduce bias.
Finally, this study may provide the possibility to make 
new and improved guidelines on mNC- FET for use on a 
national as well as international basis, the aim being to 
increase success rates of FET cycles, reduce the time from 
start of treatment to pregnancy, and reduce the expenses 
and inconvenience following ART. Furthermore, the 
investigation of several aspects of success related to ART, 
from pregnancy to live births, brings forward important 
information on luteal phase progesterone support and 
timing of blastocyst transfer in mNC- FET.
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